Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Pasireotide (Signifor) Peptide
Multi-receptor somatostatin analog for Cushing's disease and acromegaly.
What is Pasireotide (Signifor)?
Pasireotide (Signifor) is a somatostatin analog · endocrine peptide studied for cushing's disease and acromegaly (lar formulation). Below is an educational overview of Pasireotide (Signifor) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Signifor, Signifor LAR
Cushing's disease (when surgery isn't an option or has failed) and acromegaly.
A somatostatin analog that lowers ACTH or growth hormone — often used when other treatments haven't worked.
- •Diarrhea
- •Nausea
- •Hyperglycemia (very common)
- •Gallstones
- •Headache
- •New or worsening diabetes (frequently severe)
- •QT prolongation and arrhythmia
- •Bradycardia
- •Liver enzyme elevation
- •Adrenal insufficiency
- •Uncontrolled diabetes (caution)
- •Long QT syndrome
- •Severe liver disease
- •Bradyarrhythmias
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Pasireotide (Signifor) Mechanism of Action
Cyclohexapeptide somatostatin analog binding somatostatin receptors SST1, 2, 3, and 5 (with highest affinity for SST5), suppressing ACTH in corticotroph adenomas and GH/IGF-1 in somatotroph tumors.
Pasireotide (Signifor) Research Areas & Benefits
Pasireotide (Signifor) Dosage & Common Research Protocols
0.3–0.9 mg SC twice daily, titrated to cortisol response.
20–60 mg IM every 28 days.
Protocols summarized for educational reference from published research. Not dosing guidance.
Pasireotide (Signifor) Studies & Cited Research
Pasireotide in Cushing's disease (Phase III)
Reduced urinary free cortisol with dose-dependent hyperglycemia.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Pasireotide (Signifor) Side Effects & Safety Considerations
- •FDA-approved.
- •Significant hyperglycemia risk requires glucose monitoring.
- •Bradycardia and QT prolongation possible.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.